

DRUG QUANTITY MANAGEMENT POLICY – PER RX

POLICY: Oncology – Cometriq Drug Quantity Management Policy – Per Rx

- Cometriq® (cabozantinib capsules – Exelixis)

REVIEW DATE: 03/09/2022

OVERVIEW

Cometriq, a kinase inhibitor, is indicated for the treatment of patients with progressive, metastatic **medullary thyroid cancer**.¹

Dosing

The recommended dose for medullary thyroid cancer is Cometriq 140 mg once daily without food until disease progression or unacceptable toxicity.¹

Off-Label Use

The dosing used in clinical trials for differentiated thyroid cancer was cabozantinib 60 mg daily.² The dosing used in clinical trials for non-small cell lung cancer was Cometriq 60 mg to 100 mg once daily.³⁻⁴

Availability

Cometriq is available as a 20 mg and 80 mg capsule, which are supplied in daily dose cartons. Each daily dose carton contains four blister cards and each blister card is a 7-day supply.¹

Product	Packet Size	Quantity
Cometriq® (cabozantinib capsules)	140 mg daily dose carton	4 x (7 x 80 mg capsules + 21 x 20 mg capsules)
	100 mg daily dose carton	4 x (7 x 80 mg capsules + 7 x 20 mg capsules)
	60 mg daily dose carton	4 x (21 x 20 mg capsules)

Dose Modifications

The daily Cometriq dose should be increased by 40 mg as tolerated if used concomitantly with a strong cytochrome P450 (CYP)3A4 inducers. The daily dose should not exceed 180 mg. Dose may also need to be adjusted to manage adverse events, for hepatic impairment, and for coadministration with strong CYP3A inhibitors.¹

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Cometriq. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Automation: None.

Drug Quantity Limits

Product	Package Size	Maximum Quantity per Rx
Cometriq® (cabozantinib capsules)	60 mg daily dose carton	1 carton
	100 mg daily dose carton	1 carton
	140 mg daily dose carton	1 carton

CRITERIA

Cometriq 100 mg daily dose carton:

1. If a patient is taking Cometriq concomitantly with a CYP3A4 inducer, approve up to two daily dose cartons per dispensing.

REFERENCES

1. Cometriq® capsules [prescribing information]. San Francisco, CA: Exelixis; October 2020.
2. Brose MS, Robinson B, Sherman S, et al. Cabozantinib for radioactive-refractory differentiated thyroid cancer (COSMIC-311): a randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2021; 22(8):1126-1138.
3. Drilon A, Rekhman N, Arcila M, et al. Cabozantinib in patients with advanced *RET*-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. *Lancet Oncol.* 2016; 17(12):1653-1660.
4. Hellerstedt BA, Vogelzang NJ, Kluger HM. Results of a phase II placebo-controlled randomized discontinued trial of cabozantinib in patients with non-small cell lung cancer. *Clin Lung Cancer.*2019; 20(2):74-81.